retatrutide phase 2 trial dose escalation schedule Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized 2a Eli Lilly just announced striking

This can lead to direct damage to cellular organelles including mitochondria

Studies conducted on humans and preclinical models have shown that following systemic injection, EV levels in the blood drop off quickly, and that EVs tend to concentrate in the liver, spleen, and lungs for around ten days

Biochem Biophys Res Commun 505(2):523529 Daniels SJ, Leeming DJ, Detlefsen S, Bruun MF, Hjuler ST, Henriksen K, Hein P, Karsdal MA, Brockbank S, Cruwys S (2019) Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-) agonist and a glucagon-like peptide-1 analogue

Diabetes Care 2010;33:12551261

If you need or want some work done I would definitely refer you to these docs. K.D